The endocannabinoid system as a target for addiction treatment: Trials and tribulations

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Neuropharmacology

• Publication date

  2017-09-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.neuropharm.2017.05.031PMID 28564576
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence (Review)

  2019cited by this paper
• Severity of alcohol dependence is associated with the fatty acid amide hydrolase Pro129Thr missense variant

  2018cited by this paper
• Cannabidiol reduces ethanol consumption, motivation and relapse in mice

  2018cited by this paper
• Buprenorphine for managing opioid withdrawal.

  2017cited by this paper
• Chapter 6 – The Role of the Endocannabinoid System in Addiction

  2017cited by this paper
• The endocannabinoid hydrolysis inhibitor SA‐57: Intrinsic antinociceptive effects, augmented morphine‐induced antinociception, and attenuated heroin seeking behavior in mice

  2017cited by this paper
• Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users

  2016cited by this paper
• What does addiction medicine expect from neuroscience? From genes and neurons to treatment responses.

  2016cited by this paper
• Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase.

  2016cited by this paper
• Pharmacological Treatment of Cannabis-Related Disorders: A Narrative Review.

  2016cited by this paper
• Endocannabinoid Modulation of Orbitostriatal Circuits Gates Habit Formation.

  2016cited by this paper
• Rapid Changes in Cannabinoid 1 Receptor Availability in Cannabis-Dependent Male Subjects After Abstinence From Cannabis.

  2016cited by this paper
• Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence

  2016cited by this paper
• X-ray structure of the human α4β2 nicotinic receptor

  2016cited by this paper
• Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys

  2016cited by this paper
• The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability

  2016cited by this paper
• Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis

  2016cited by this paper
• Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial.

  2016cited by this paper
• Alpha₂-adrenergic agonists for the management of opioid withdrawal.

  2016cited by this paper
• Increases in Drug and Opioid Overdose Deaths--United States, 2000-2014.

  2016cited by this paper
• Nicotine receptor partial agonists for smoking cessation.

  2016cited by this paper
• Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015

  2016cited by this paper
• Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.

  2016cited by this paper
• Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans.

  2016cited by this paper
• Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings.

  2016cited by this paper
• Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks: A Randomized Clinical Trial.

  2016cited by this paper
• Prevalence and Correlates of DSM-5 Cannabis Use Disorder, 2012-2013: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III.

  2016cited by this paper
• X-ray structure of the human alpha 4 beta 2 nicotinic receptor.

  2016cited by this paper
• Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial.

  2016cited by this paper
• Inhibition of monoacylglycerol lipase (MAGL) enhances cue-induced reinstatement of nicotine-seeking behavior in mice

  2015cited by this paper
• Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor

  2015cited by this paper
• Inhibition of monoacylglycerol lipase reduces nicotine withdrawal

  2015cited by this paper
• Safety of oral dronabinol during opioid withdrawal in humans.

  2015cited by this paper
• The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.

  2015cited by this paper
• Endocannabinoid signaling in reward and addiction

  2015cited by this paper
• Safety and Pharmacokinetics of Oral Cannabidiol When Administered Concomitantly With Intravenous Fentanyl in Humans

  2015cited by this paper
• Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage

  2015cited by this paper
• Blocking of Fatty Acid Amide Hydrolase Activity with PF-04457845 in Human Brain: A Positron Emission Tomography Study with the Novel Radioligand [11C]CURB

  2015cited by this paper
• Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.

  2015cited by this paper
• Preview : Published ahead of advance online publication Species Differences in Cannabinoid Receptor 2 and Receptor Responses to Cocaine Self-Administration in Mice and Rats

  2014cited by this paper
• Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

  2014cited by this paper
• Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.

  2014cited by this paper
• Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial.

  2014cited by this paper
• Pharmacotherapies for cannabis dependence.

  2014cited by this paper
• Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice

  2014cited by this paper
• CB2 Cannabinoid Receptors as a Therapeutic Target—What Does the Future Hold?

  2014cited by this paper
• Methadone at tapered doses for the management of opioid withdrawal.

  2013cited by this paper
• Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.

  2013cited by this paper
• The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users.

  2013cited by this paper
• Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity

  2013cited by this paper
• Subjective, cognitive and cardiovascular dose‐effect profile of nabilone and dronabinol in marijuana smokers

  2013cited by this paper
• Pharmacological interventions for smoking cessation: an overview and network meta-analysis.

  2013cited by this paper
• Role of CB2 Cannabinoid Receptors in the Rewarding, Reinforcing, and Physical Effects of Nicotine

  2013cited by this paper
• The cannabinoid CB2 receptor is necessary for nicotine-conditioned place preference, but not other behavioral effects of nicotine in mice

  2013cited by this paper
• Dual Inhibition of Endocannabinoid Catabolic Enzymes Produces Enhanced Antiwithdrawal Effects in Morphine-Dependent Mice

  2013cited by this paper
• Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings.

  2013cited by this paper
• Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity

  2013cited by this paper
• Nabilone Decreases Marijuana Withdrawal and a Laboratory Measure of Marijuana Relapse

  2013cited by this paper
• Effects of a Selective Cannabinoid CB2 Agonist and Antagonist on Intravenous Nicotine Self Administration and Reinstatement of Nicotine Seeking

  2012cited by this paper
• An efficient randomised, placebo‐controlled clinical trial with the irreversible fatty acid amide hydrolase‐1 inhibitor PF‐04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee

  2012cited by this paper
• Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects.

  2012cited by this paper
• Quantifying the Clinical Significance of Cannabis Withdrawal

  2012cited by this paper
• Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers

  2012cited by this paper
• Efficacy of a dose range of surinabant, a cannabinoid receptor blocker, for smoking cessation: a randomized controlled clinical trial

  2012cited by this paper
• AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.

  2012cited by this paper
• Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial.

  2011cited by this paper
• Blockade of Endocannabinoid Hydrolytic Enzymes Attenuates Precipitated Opioid Withdrawal Symptoms in Mice

  2011cited by this paper
• Safety and side effects of cannabidiol, a Cannabis sativa constituent.

  2011cited by this paper
• Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.

  2011cited by this paper
• Brain Cannabinoid CB2 Receptors Modulate Cocaine’s Actions in Mice

  2011cited by this paper
• A Randomized, Controlled Study to Investigate the Analgesic Efficacy of Single Doses of the Cannabinoid Receptor-2 Agonist GW842166, Ibuprofen or Placebo in Patients With Acute Pain Following Third Molar Tooth Extraction

  2011cited by this paper
• Cannabinoid type 1 receptor antagonists for smoking cessation.

  2011cited by this paper
• Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.

  2011cited by this paper
• Randomized, controlled, double-blind trial of taranabant for smoking cessation

  2010cited by this paper
• Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.

  2010cited by this paper
• Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology

  2010cited by this paper
• Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142.

  2010cited by this paper
• Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625

  2010cited by this paper
• CB1 receptor blockade decreases ethanol intake and associated neurochemical changes in fawn-hooded rats.

  2010cited by this paper
• Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved.

  2009cited by this paper
• Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo

  2009cited by this paper
• Cannabidiol, a Nonpsychotropic Component of Cannabis, Inhibits Cue-Induced Heroin Seeking and Normalizes Discrete Mesolimbic Neuronal Disturbances

  2009cited by this paper
• Inhibitors of Endocannabinoid-Metabolizing Enzymes Reduce Precipitated Withdrawal Responses in THC-Dependent Mice

  2009cited by this paper
• Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration—comparison with CB1 receptor blockade

  2009cited by this paper
• Rimonabant (SR141716) has no effect on alcohol self-administration or endocrine measures in nontreatment-seeking heavy alcohol drinkers

  2009cited by this paper
• A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain.

  2009cited by this paper
• Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects

  2008cited by this paper
• TRPV2 Is Activated by Cannabidiol and Mediates CGRP Release in Cultured Rat Dorsal Root Ganglion Neurons

  2008cited by this paper
• Cannabinoid Receptor 1 Blocker Rimonabant (SR 141716) for Treatment of Alcohol Dependence: Results From a Placebo-Controlled, Double-Blind Trial

  2008cited by this paper
• Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse

  2008cited by this paper
• Blockade of THC-Seeking Behavior and Relapse in Monkeys by the Cannabinoid CB1-Receptor Antagonist Rimonabant

  2008cited by this paper
• Long term pharmacotherapy for obesity and overweight: updated meta-analysis

  2007cited by this paper
• Randomized controlled trial of cannabis‐based medicine in spasticity caused by multiple sclerosis

  2007cited by this paper
• Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.

  2007cited by this paper
• Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms.

  2007cited by this paper
• Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users

  2007cited by this paper
• overweight: updated meta-analysis Long term pharmacotherapy for obesity and

  2007cited by this paper
• Specific Alterations of Extracellular Endocannabinoid Levels in the Nucleus Accumbens by Ethanol, Heroin, and Cocaine Self-Administration

  2007cited by this paper
• Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro

  2007cited by this paper
• Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats

  2005cited by this paper

• Dose- and sex-related effects of the MAGL inhibitor MCH11 on binge-like ethanol consumption in mice.

  2026cites this paper
• Effectiveness of cognitive behavioral therapy for harmful cannabis use: a systematic review and meta-analysis.

  2026cites this paper
• A Preliminary Investigation of Brain Cannabinoid Receptor Type 1 (CB1R) Availability in Men with Opioid Use Disorder

  2025cites this paper
• The safety and efficacy of cannabinoids for the treatment of mental health and substance use disorders: protocol for a systematic review and meta-analysis

  2025cites this paper
• Efficacy of cannabidiol alone or in combination with Δ‐9‐tetrahydrocannabinol for the management of substance use disorders: An umbrella review of the evidence

  2025cites this paper
• Associations Between Cannabis Use and Mental Health in Patients Accessing Treatment for Substance Use Disorders: An Exploratory Cross-Sectional Study

  2025cites this paper
• Endocannabinoids and related lipids linked to social exclusion in individuals with chronic non-medical prescription opioid use

  2024cites this paper
• AM6527, a neutral CB1 receptor antagonist, suppresses opioid taking and seeking, as well as cocaine seeking in rodents without aversive effects

  2024cites this paper
• Alcohol Use Disorder and Chronic Pain: An Overlooked Epidemic.

  2024cites this paper
• Endocannabinoid agonist 2-arachidonoylglycerol differentially alters diurnal activity and sleep during fentanyl withdrawal in male and female mice.

  2024cites this paper
• Evidence from Human Studies for Utilising Cannabinoids for the Treatment of Substance-Use Disorders: A Scoping Review with a Systematic Approach

  2023cites this paper
• Anandamide and 2-arachidonoylglycerol baseline plasma concentrations and their clinical correlate in gambling disorder

  2023cites this paper
• Dysregulation of the endogenous cannabinoid system following opioid exposure.

  2023cites this paper
• Fatty Acid Amide Hydrolase, Neurodevelopment, and Alcohol: Illuminating the Intricacies of the Endocannabinoid System in Addiction Susceptibility.

  2023cites this paper
• Cannabidiol as a Harm Reduction Strategy for People Who Use Drugs: A Rapid Review

  2023cites this paper
• Cannabinoids for Substance Use Disorder Treatment: What Does the Current Evidence Say?

  2023cites this paper
• Molecular brain differences and cannabis involvement: A systematic review of positron emission tomography studies.

  2023cites this paper
• Consuming oral cannabidiol prior to a standard alcohol dose has minimal effect on breath alcohol level and subjective effects of alcohol

  2023cites this paper
• Sex-specific Effects of the Endocannabinoid Agonist 2-Arachidonoylglycerol on Sleep and Circadian Disruptions during Fentanyl Withdrawal

  2023cites this paper
• Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals

  2022cites this paper
• Neutral CB1 Receptor Antagonists as Pharmacotherapies for Substance Use Disorders: Rationale, Evidence, and Challenge

  2022cites this paper
• Neuroscientific Basis of Treatment for Substance Use Disorders.

  2022cites this paper
• Endocannabinoids regulate cocaine-associated memory through brain AEA–CB1R signalling activation

  2022cites this paper
• The effects of acute alcohol administration on circulating endocannabinoid levels in humans

  2022cites this paper
• Helpful or Harmful? The Therapeutic Potential of Medications with Varying Degrees of Abuse Liability in the Treatment of Substance Use Disorders

  2022influential citation
• Therapeutic potential of PIMSR, a novel CB1 receptor neutral antagonist, for cocaine use disorder: evidence from preclinical research

  2022cites this paper
• Alcohol-Endocannabinoid Interactions: Implications for Addiction-Related Behavioral Processes

  2022cites this paper
• Efficiency of Inhaled Cannabidiol in Cannabis Use Disorder: The Pilot Study Cannavap

  2022cites this paper
• Effects of waterpipe tobacco smoke and ceftriaxone treatment on the expression of endocannabinoid receptors in mesocorticolimbic brain regions.

  2022cites this paper
• Cannabidiol as a treatment for craving and relapse in individuals with cocaine use disorder: a randomized placebo‐controlled trial

  2021cites this paper
• Cannabidiol and the central nervous system: translating into clinics

  2021cites this paper
• Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders

  2021cites this paper
• Contribution of Fatty Acid Amide Hydrolase to Alcohol Use Disorder: A Systematic Review

  2021cites this paper
• Cannabinoid Drugs in Mental Health Disorders

  2021cites this paper
• PMSF Attenuates Morphine Antinociceptive Tolerance and Dependence in Mice: Its Association with the Oxidative Stress Suppression

  2021cites this paper
• Cannabidiol reduces withdrawal symptoms in nicotine-dependent rats

  2021cites this paper
• The Endocannabinoid System and Alcohol Dependence: Will Cannabinoid Receptor 2 Agonism be More Fruitful than Cannabinoid Receptor 1 Antagonism?

  2021cites this paper
• Restoring glutamate homeostasis in the nucleus accumbens via endocannabinoid-mimetic drug prevents relapse to cocaine seeking behavior in rats

  2021cites this paper
• The endocannabinoid system and drug-associated contextual memories

  2021cites this paper
• PET Imaging of the Endocannabinoid System

  2020cites this paper
• Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-TH1A and TRPV1 receptor mechanisms.

  2020cites this paper
• Lower brain fatty acid amide hydrolase in treatment-seeking patients with alcohol use disorder: a positron emission tomography study with [C-11]CURB

  2020cites this paper
• GPCR and Alcohol-Related Behaviors in Genetically Modified Mice

  2020cites this paper
• Understanding the neurobiological effects of drug abuse: Lessons from zebrafish models.

  2020cites this paper
• Possible therapeutic applications of cannabis in the neuropsychopharmacology field.

  2020cites this paper
• Therapeutic potential of opioid/cannabinoid combinations in humans: Review of the evidence.

  2020cites this paper
• Xie2-64, a novel CB2R ligand, reduces cocaine abuse-related behaviors in rodents.

  2020cites this paper
• Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models.

  2020cites this paper
• Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date

  2020cites this paper
• Evaluation of anxiety-like behaviors following ethanol withdrawal in mice: effects of cannabidiol

  2020cites this paper
• Dopamine, endocannabinoids and their interaction in fear extinction and negative affect in PTSD.

  2020cites this paper
• Choosing the right drug: status and future of endocannabinoid research for the prevention of drug-seeking reinstatement.

  2020cites this paper
• Cannabinoids and the endocannabinoid system in reward processing and addiction: from mechanisms to interventions


  2020cites this paper
• Effects of the cannabinoid receptor agonist CP-55,940 on incentive salience attribution

  2019cites this paper
• The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder

  2019cites this paper
• Neuroimmune signaling in alcohol use disorder

  2019cites this paper
• Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders

  2019cites this paper
• Animal models in addiction research: A dimensional approach.

  2019cites this paper
• The Role of the Endocannabinoid Signaling System in the Pathophysiology of Asthma and Obesity

  2019cites this paper
• Characteristics of Patients that Substitute Medical Cannabis for Alcohol

  2019influential citation
• Randomized Clinical Trials Investigating Innovative Interventions for Smoking Cessation in the Last Decade.

  2019cites this paper
• Characteristics of Dispensary Patients that Limit Alcohol after Initiating Cannabis

  2019cites this paper
• Development of Oxygen-Bridged Pyrazole-Based Structures as Cannabinoid Receptor 1 Ligands

  2019cites this paper
• Cannabinoids and the Microbiota-Gut-Brain-Axis: Emerging Effects of Cannabidiol and Potential Applications to Alcohol Use Disorders.

  2019cites this paper
• The Treatment of Cannabis Use Disorder

  2019cites this paper
• Involvement of Activated Brain Stress Responsive Systems in Excessive and “Relapse” Alcohol Drinking in Rodent Models: Implications for Therapeutics

  2018cites this paper
• Cannabis Use: Neurobiological, Behavioral, and Sex/Gender Considerations

  2018cites this paper
• The Molecular Basis of Cannabinoid Activity: Application to Therapeutics Design and Discovery for Cannabis Use Disorders

  2018cites this paper
• The role of medical cannabis in the opioid crisis

  2018cites this paper
• Quantification of Eight Cannabinoids Including Cannabidiol in Human Urine Via Liquid Chromatography Tandem Mass Spectrometry.

  2018cites this paper
• When orexins meet cannabinoids: Bidirectional functional interactions.

  2018cites this paper
• Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies

  2018cites this paper
• Highway to hell or magic smoke? The dose-dependence of Δ9-THC in place conditioning paradigms

  2018cites this paper
• Understanding the implications of the biobehavioral basis of nicotine addiction and its impact on the efficacy of treatment

  2018cites this paper
• Brain activity of anandamide: a rewarding bliss?

  2018cites this paper
• Ethnopharmacology of Love

  2018cites this paper
• THC inhibits the expression of ethanol-induced locomotor sensitization in mice.

  2017cites this paper
• Medications for substance use disorders (SUD): emerging approaches

  2017cites this paper
• Effects of Cannabinoid Drugs on Aversive or Rewarding Drug-Associated Memory Extinction and Reconsolidation.

  2017cites this paper
• Precision Nutrition and Omega-3 Polyunsaturated Fatty Acids: A Case for Personalized Supplementation Approaches for the Prevention and Management of Human Diseases

  2017cites this paper
• Cannabis, cannabinoids, and health

  2017cites this paper
• A new dawn in cannabinoid neurobiology: The road from molecules to therapeutic discoveries.

  2017cites this paper